| | Dr. Nierenberg is interested in the clinical pharmacology of antioxidant micronutrients and vitamins, and their role in health and disease prevention. He is also interested in the clinical pharmacology and pharmacodynamics of methotrexate and other antineoplastic agents. He is the director of the Clinical Pharmacology Shared Service of the Comprehensive Cancer Center.
Dr. Nierenberg received his B.A. degree from Harvard College in 1971, took a fellowship at Oxford University for one year, and received his M.D. degree from Harvard Medical School in 1976. He performed his internship and residency in internal medicine at the Beth Israel Hospital in Boston, and completed a two-year clinical/research fellowship in clinical pharmacology at the University of California, San Francisco. In 1980-81 he was invited to the Stanford Medical Center to be chief medical resident. In 1981 he joined the faculty at Dartmouth Medical School and established a new Division of Clinical Pharmacology. The new Division has been active in the areas of basic and clinical research, clinical care and consultations, and establishing educational programs for medical students and residents.
At Dartmouth, much of Dr. Nierenberg's initial work focussed on drug interactions between methotrexate and other drugs which share the same renal secretory pathway. Through a combination of in vitro and clinical studies, Dr. Nierenberg demonstrated that drugs which interact with methotrexate to increase toxicity can often be identified with an in vitro laboratory model of tubular secretion.
A second area of research has involved studies of the cancer chemopreventive effects of fat-soluble vitamins. In collaboration with Drs. Greenberg, Baron, and Colacchio, Dr. Nierenberg has been active in studying the clinical pharmacology of retinol, beta-carotene, and alpha-tocopherol, and also studying their abilities to prevent cancer in high-risk patients. Most recently, his work has extended to the study of the clinical pharmacology of these fat-soluble vitamins in patients with a variety of malignant and benign diseases; as well as the clinical pharmacology of various anticancer drugs.
|
